BLFS / BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates

BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023. more_horizontal

BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year more_horizontal

BioLife Solutions said it is divesting itself of some assets to focus on its higher-margin business. The company saw declining revenue but narrowed it more_horizontal

On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 share more_horizontal

On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 share more_horizontal

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Michael Ric more_horizontal

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares more_horizontal

BioLife Solutions, a leading provider of bioproduction tools and services, is poised for growth as the demand for biologics and regenerative medicine more_horizontal